Denali Therapeutics Inc.

Sector and Industry

Healthcare, Biopharmaceuticals

Performance (1Y)

61.57%

Market Cap

-

P/E Ratio

0.00

Dividend Yield

0.00 %

Earnings per Share

-2.63 €

Peer Group

Company NameMarket CapRevenue Last Reported YearP/E RatioProfit Growth 1YLast PricePrevious Trading Day Change
Eli Lilly and Company864.54 Bil.57.78 Bil.46.82
+86.88 %
0.00
-
Johnson & Johnson425.70 Bil.83.48 Bil.18.82
+82.71 %
0.00
-
AbbVie Inc.343.94 Bil.54.21 Bil.96.78
-5.29 %
0.00
-
Roche Holding AG286.62 Bil.65.80 Bil.20.72
+58.45 %
0.00
-
AstraZeneca PLC244.91 Bil.52.09 Bil.27.55
+39.41 %
0.00
-
NOVARTIS AG 224.76 Bil.48.44 Bil.18.30
+12.45 %
0.00
-
Merck & Co. Inc.221.79 Bil.57.55 Bil.14.46
+2.25 %
0.00
-
Novo-Nordisk AS B193.52 Bil.41.49 Bil.14.11
+1.54 %
0.00
-
Amgen Inc.150.16 Bil.32.57 Bil.23.01
+80.77 %
0.00
-
Gilead Sciences Inc.129.70 Bil.26.10 Bil.18.10
+1,599.93 %
0.00
-

Facts & figures

Price data

TRADE PLATFORMBörse Stuttgart (XSTU)
LAST PRICE20.4 G0 Units
PRICE DETERMINATION TIME07/21/2026 / 04:31:53 PM
DAILY VOLUME (UNITS)0
DAILY HIGH / LOW20.419.765
PREV. DAY'S PRICE20.04 (07/20)
CHANGE DAY BEFORE
+0.36
1.80 %
52 WEEK HIGH / LOW23.8 (07/09)10.895 (09/22)
More Price Information

Key Figures (in EUR)

2023202420252026e2027e
EARNINGS PER SHARE
-0.98-2.38-2.63-2.35-2.09
DIVIDENDS PER SHARE
0.000.000.000.000.00
DIVIDEND YIELD IN %
0.00 %0.00 %0.00 %--
DIVIDEND GROWTH IN %
-----
PRICE - EARNINGS RATIO
-----
PRICE - BOOK RATIO
2.882.362.54--
PRICE - SALES RATIO
8.92----
PRICE - CASH FLOW RATIO
-----
Further Key Figures

Master Data

WKN
A2H9G8
ISIN
US24823R1059
SYMBOL
4DN
EXCHANGE SEGMENT
Freiverkehr
TYPE OF FINANCIAL INSTRUMENT
Equity
DENOMINATION
DENALI THERAP.INC. DL-,01
INDEX MEMBERSHIP
-
TRADING SEGMENT
-
TRADING HOURS
07:30:00 AM - 10:00:00 PM
TRADING CURRENCY
Euro
NOMINAL CURRENCY
-
SETTLEMENT CURRENCY
Euro
SECTOR AND INDUSTRYHealthcare, Biopharmaceuticals
NUMBER OF SHARES
-
MARKET CAPITALISATION
-

Performance overview

1W1M3M6M1Y3Y5YYTD
PERFORMANCE
-13.66 %
0.25 %
15.34 %
31.26 %
61.57 %
-21.04 %
-62.79 %
43.91 %
HIGH23.0723.8023.8023.8023.8030.7160.0023.80
LOW19.2619.2615.2614.6910.909.749.7413.19

Dividende

pro Aktie
DENALI THERAP.INC. DL-,01 does not deliver dividend information

Company profile

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

Shareholder Structure (Top 10)

AnteilName
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available

Analyst Rating

Ø-Target Price DistanceNot Available
Current Price
Not Available
Ø-Target Price
Not Available
Average ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0

Company Events

No company events available.